← Leaderboards
Tamar Barlam
Beth Israel Deaconess Medical Center
$983,213
Attributed
$1,966,425
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $500K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
AHRQ$1,966,425 · 1
NIH$0 · 1
By mechanism
R01$1,966,425 · 1
M01$0 · 1
Top collaborators
- Mari-Lynn Drainoni4 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Nira Pollock$9,552,528
- Michael B Atkins$4,622,469
- Richard P Junghans$3,490,049
- Michael O'Donnell$0
- Norman L Letvin$50,955,616
Others in their field
Top investigators on “Bacillus Calmette Guerin Vaccine”
- Donald L Morton · John Wayne Cancer Institute$6,163,134
- Charles A. Scanga · University Of Pittsburgh At Pittsburgh$5,049,872
- Jacqueline Michele Achkar · Albert Einstein College Of Medicine$4,131,033
- Jeffrey K Actor · Pharmareview Corporation$3,782,167
- William Robert Jacobs · Albert Einstein College Of Medicine$3,654,302
- Donald L Sodora · Seattle Children'S Hospital$3,489,051
Research focus
Bacillus Calmette Guerin VaccineBacterial DiseaseBladder NeoplasmClinical ResearchDisease /Disorder Proneness /RiskDrug Adverse EffectHuman SubjectIatrogenic DiseaseImmunogeneticsImmunopathologyMicroorganism ImmunologyMycobacteriumNeoplasm /Cancer ImmunotherapyPathologic Process
Grant awards (9)
Implementing Telemedicine to Improve Appropriate Antibiotic Prescribing for Acute Respiratory Tract Infections$483,567
R01 · FY2025 · HS · contact PI
Implementing Telemedicine to Improve Appropriate Antibiotic Prescribing for Acute Respiratory Tract Infections$487,417
R01 · FY2024 · HS · contact PI
Implementing Telemedicine to Improve Appropriate Antibiotic Prescribing for Acute Respiratory Tract Infections$495,441
R01 · FY2023 · HS · contact PI
Implementing Telemedicine to Improve Appropriate Antibiotic Prescribing for Acute Respiratory Tract Infections$500,000
R01 · FY2022 · HS · contact PI
RISK FACTOR FOR BCGOSIS AFTER INTRAVESICULAR BCG IMMUNOTHERAPY$0
M01 · FY2002 · RR
RISK FACTOR FOR BCGOSIS AFTER INTRAVESICULAR BCG IMMUNOTHERAPY$0
M01 · FY2001 · RR
RISK FACTOR FOR BCGOSIS AFTER INTRAVESICULAR BCG IMMUNOTHERAPY$0
M01 · FY2000 · RR
RISK FACTOR FOR BCGOSIS AFTER INTRAVESICULAR BCG IMMUNOTHERAPY$0
M01 · FY2000 · RR
RISK FACTOR FOR BCGOSIS AFTER INTRAVESICULAR BCG IMMUNOTHERAPY$0
M01 · FY2000 · RR